BridgeMD
A Phase 1/2a Study of BMS-986507 (BL-B01D1) in Adult Participants with Advanced Solid Tumors
EU CTIS ID: 2024-514947-27-00
What this study is testing
Find out if BMS-986507 is safe and to determine the maximum dose that is safe for being given to the patients in combination with other treatments and select some safe doses to be evaluated in a large group of patients. BMS-986507 will be evaluated in two groups of lung cancer patients: patients with a type of lung cancer called EGFRmt non-small cell lung cancer (NSCLC) and patients with a type of lung cancer called EGFRwt NSCLC.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
- Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Participants must have a life expectancy of at least 3 months at the time of the first dose.
You likely can't join if
- Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
- Participants with spinal cord compression, symptomatic central nervous system (CNS) metastases, progression of existing CNS metastases, or the appearance of new lesions as shown on CNS imaging during screening will be excluded.
- Participants must not have a history of serious recurrent infections.
- Participants must not have a history of severe heart disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- United Kingdom
- Australia
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; United Kingdom; Australia; Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.